These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 11684808)
1. Response to Shiga toxin-1, with and without lipopolysaccharide, in a primate model of hemolytic uremic syndrome. Siegler RL; Pysher TJ; Lou R; Tesh VL; Taylor FB Am J Nephrol; 2001; 21(5):420-5. PubMed ID: 11684808 [TBL] [Abstract][Full Text] [Related]
2. Response to single and divided doses of Shiga toxin-1 in a primate model of hemolytic uremic syndrome. Siegler RL; Pysher TJ; Tesh VL; Taylor FB J Am Soc Nephrol; 2001 Jul; 12(7):1458-1467. PubMed ID: 11423574 [TBL] [Abstract][Full Text] [Related]
3. von Willebrand Factor expression in a Shiga toxin-mediated primate model of hemolytic uremic syndrome. Pysher TJ; Siegler RL; Tesh VL; Taylor FB Pediatr Dev Pathol; 2002; 5(5):472-9. PubMed ID: 12196894 [TBL] [Abstract][Full Text] [Related]
4. Renal prostacyclin biosynthesis in a baboon model of Shiga toxin mediated hemolytic uremic syndrome. Siegler RL; Pysher TJ; Tesh VL; Taylor FB Nephron; 2002 Oct; 92(2):363-8. PubMed ID: 12218315 [TBL] [Abstract][Full Text] [Related]
5. Response to Shiga toxin 1 and 2 in a baboon model of hemolytic uremic syndrome. Siegler RL; Obrig TG; Pysher TJ; Tesh VL; Denkers ND; Taylor FB Pediatr Nephrol; 2003 Feb; 18(2):92-6. PubMed ID: 12579394 [TBL] [Abstract][Full Text] [Related]
6. Lipopolysaccharide upregulates renal shiga toxin receptors in a primate model of hemolytic uremic syndrome. Clayton F; Pysher TJ; Lou R; Kohan DE; Denkers ND; Tesh VL; Taylor FB; Siegler RL Am J Nephrol; 2005; 25(6):536-40. PubMed ID: 16179829 [TBL] [Abstract][Full Text] [Related]
7. Hemolytic uremic syndrome induced by lipopolysaccharide and Shiga-like toxin. Ikeda M; Ito S; Honda M Pediatr Nephrol; 2004 May; 19(5):485-9. PubMed ID: 15007712 [TBL] [Abstract][Full Text] [Related]
8. Prophylactic heparinization is ineffective in a primate model of hemolytic uremic syndrome. Siegler RL; Pysher TJ; Tesh VL; Denkers ND; Taylor FB Pediatr Nephrol; 2002 Dec; 17(12):1053-8. PubMed ID: 12478357 [TBL] [Abstract][Full Text] [Related]
9. Reduced nitric oxide bioavailability in a baboon model of Shiga toxin mediated hemolytic uremic syndrome (HUS). Siegler RL; Pysher TJ; Tesh VL; Noris M; Cassis P; Taylor FB Ren Fail; 2005; 27(5):635-41. PubMed ID: 16153006 [TBL] [Abstract][Full Text] [Related]
10. Mouse model for hemolytic uremic syndrome induced by outer membrane vesicles of Escherichia coli O157:H7. Kim SH; Lee YH; Lee SH; Lee SR; Huh JW; Kim SU; Chang KT FEMS Immunol Med Microbiol; 2011 Dec; 63(3):427-34. PubMed ID: 22029600 [TBL] [Abstract][Full Text] [Related]
11. Human monocytes stimulated by Shiga toxin 1a via globotriaosylceramide release proinflammatory molecules associated with hemolytic uremic syndrome. Brigotti M; Carnicelli D; Arfilli V; Porcellini E; Galassi E; Valerii MC; Spisni E Int J Med Microbiol; 2018 Oct; 308(7):940-946. PubMed ID: 29983334 [TBL] [Abstract][Full Text] [Related]
12. The CXCR4/CXCR7/SDF-1 pathway contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome in humans and mice. Petruzziello-Pellegrini TN; Yuen DA; Page AV; Patel S; Soltyk AM; Matouk CC; Wong DK; Turgeon PJ; Fish JE; Ho JJ; Steer BM; Khajoee V; Tigdi J; Lee WL; Motto DG; Advani A; Gilbert RE; Karumanchi SA; Robinson LA; Tarr PI; Liles WC; Brunton JL; Marsden PA J Clin Invest; 2012 Feb; 122(2):759-76. PubMed ID: 22232208 [TBL] [Abstract][Full Text] [Related]
13. Distinct renal pathology and a chemotactic phenotype after enterohemorrhagic Escherichia coli shiga toxins in non-human primate models of hemolytic uremic syndrome. Stearns-Kurosawa DJ; Oh SY; Cherla RP; Lee MS; Tesh VL; Papin J; Henderson J; Kurosawa S Am J Pathol; 2013 Apr; 182(4):1227-38. PubMed ID: 23402998 [TBL] [Abstract][Full Text] [Related]
14. Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1. Taylor FB; Tesh VL; DeBault L; Li A; Chang AC; Kosanke SD; Pysher TJ; Siegler RL Am J Pathol; 1999 Apr; 154(4):1285-99. PubMed ID: 10233866 [TBL] [Abstract][Full Text] [Related]
15. Pathogenesis of Shiga toxin-induced hemolytic uremic syndrome. Ray PE; Liu XH Pediatr Nephrol; 2001 Oct; 16(10):823-39. PubMed ID: 11605791 [TBL] [Abstract][Full Text] [Related]
16. Diet-induced obesity precipitates kidney dysfunction and alters inflammatory mediators in mice treated with Shiga Toxin 2. Harrison LM; Gaines DW; Babu US; Balan KV; Reimschuessel R; Do AB; Pereira MR; Bigley EC; Ferguson M; Mehta A; Williams KM Microb Pathog; 2018 Oct; 123():250-258. PubMed ID: 30016681 [TBL] [Abstract][Full Text] [Related]
17. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. Morigi M; Galbusera M; Gastoldi S; Locatelli M; Buelli S; Pezzotta A; Pagani C; Noris M; Gobbi M; Stravalaci M; Rottoli D; Tedesco F; Remuzzi G; Zoja C J Immunol; 2011 Jul; 187(1):172-80. PubMed ID: 21642543 [TBL] [Abstract][Full Text] [Related]
19. The efficacy of recombinant human soluble thrombomodulin for the treatment of shiga toxin-associated hemolytic uremic syndrome model mice. Suyama K; Kawasaki Y; Miyazaki K; Kanno S; Ono A; Ohara S; Sato M; Hosoya M Nephrol Dial Transplant; 2015 Jun; 30(6):969-77. PubMed ID: 25694534 [TBL] [Abstract][Full Text] [Related]